Literature DB >> 29241410

Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.

Abdul Rafeh Naqash1, Chipman Robert Geoffrey Stroud1, Muhammad Umer Butt2, Grace K Dy3, Aparna Hegde1, Mahvish Muzaffar1, Li V Yang1, Maida Hafiz4, Cynthia R Cherry5, Paul R Walker5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29241410      PMCID： PMC5990460          DOI： 10.1080/0284186X.2017.1415460

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  26 in total

Review 1.  Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?

Authors:  Ingrid Müller; Markus Munder; Pascale Kropf; Gertrud Maria Hänsch
Journal:  Trends Immunol       Date:  2009-09-21       Impact factor: 16.687

Review 2.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

Authors:  Donald C McMillan
Journal:  Cancer Treat Rev       Date:  2012-09-17       Impact factor: 12.111

Review 3.  Biomarkers of response to PD-1/PD-L1 inhibition.

Authors:  Saman Maleki Vareki; Carmen Garrigós; Ignacio Duran
Journal:  Crit Rev Oncol Hematol       Date:  2017-06-09       Impact factor: 6.312

4.  Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Authors:  Stefan Diem; Sabine Schmid; Mirjam Krapf; Lukas Flatz; Diana Born; Wolfram Jochum; Arnoud J Templeton; Martin Früh
Journal:  Lung Cancer       Date:  2017-07-24       Impact factor: 5.705

Review 5.  Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies.

Authors:  Zubing Mei; Lu Shi; Bo Wang; Jizhen Yang; Zhihong Xiao; Peixin Du; Qingming Wang; Wei Yang
Journal:  Cancer Treat Rev       Date:  2017-05-29       Impact factor: 12.111

Review 6.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

Review 7.  Neutrophils in cancer: neutral no more.

Authors:  Seth B Coffelt; Max D Wellenstein; Karin E de Visser
Journal:  Nat Rev Cancer       Date:  2016-06-10       Impact factor: 60.716

Review 8.  Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  Nutr J       Date:  2010-12-22       Impact factor: 3.271

9.  The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer.

Authors:  K Canna; P A McArdle; D C McMillan; A-M McNicol; G W Smith; R F McKee; C S McArdle
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

10.  Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.

Authors:  P F Ferrucci; S Gandini; A Battaglia; S Alfieri; A M Di Giacomo; D Giannarelli; G C Antonini Cappellini; F De Galitiis; P Marchetti; G Amato; A Lazzeri; L Pala; E Cocorocchio; C Martinoli
Journal:  Br J Cancer       Date:  2015-05-26       Impact factor: 7.640
View more
  14 in total

Review 1.  Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer.

Authors:  Giuseppe Luigi Banna; Alex Friedlaender; Marco Tagliamento; Veronica Mollica; Alessio Cortellini; Sara Elena Rebuzzi; Arsela Prelaj; Abdul Rafeh Naqash; Edouard Auclin; Lucia Garetto; Laura Mezquita; Alfredo Addeo
Journal:  Curr Oncol Rep       Date:  2022-10-18       Impact factor: 5.945

2.  Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.

Authors:  Wenxian Wang; Zhangzhou Huang; Zongyang Yu; Wu Zhuang; Weijun Zheng; Zhijian Cai; Lei Shi; Xinmin Yu; Guangyuan Lou; Wei Hong; Yiping Zhang; Ming Chen; Zhengbo Song
Journal:  Front Oncol       Date:  2020-10-09       Impact factor: 6.244

3.  Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis.

Authors:  Zimu Wang; Ping Zhan; Yanling Lv; Kaikai Shen; Yuqing Wei; Hongbing Liu; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2019-06

4.  Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib.

Authors:  Rong Chen; Fang-Ying Lu; Bing Liu; Jingwen Huang; Min Zhou; Ranran Dai; Yi Guo
Journal:  Cancer Manag Res       Date:  2021-05-03       Impact factor: 3.989

5.  Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.

Authors:  Aixa E Soyano; Bhagirathbhai Dholaria; Julian A Marin-Acevedo; Nancy Diehl; David Hodge; Yan Luo; Rami Manochakian; Saranya Chumsri; Alex Adjei; Keith L Knutson; Yanyan Lou
Journal:  J Immunother Cancer       Date:  2018-11-23       Impact factor: 13.751

6.  Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors.

Authors:  Sanna Iivanainen; Jarkko Ahvonen; Aija Knuuttila; Satu Tiainen; Jussi Pekka Koivunen
Journal:  ESMO Open       Date:  2019-08-16

7.  Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.

Authors:  Mingjia Li; Daniel Spakowicz; Jarred Burkart; Sandip Patel; Marium Husain; Kai He; Erin M Bertino; Peter G Shields; David P Carbone; Claire F Verschraegen; Carolyn J Presley; Gregory A Otterson; Kari Kendra; Dwight H Owen
Journal:  J Cancer Res Clin Oncol       Date:  2019-07-31       Impact factor: 4.553

8.  Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors.

Authors:  Rong Chai; Yinxing Fan; Jiayi Zhao; Fan He; Jianong Li; Yiping Han
Journal:  Ann Transl Med       Date:  2020-09

Review 9.  Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).

Authors:  Wolfgang M Brueckl; Joachim H Ficker; Gloria Zeitler
Journal:  BMC Cancer       Date:  2020-12-03       Impact factor: 4.430

Review 10.  Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.

Authors:  Sanna Iivanainen; Jussi P Koivunen
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.